The Optogenerapy Project arrived to its end
After 3 intensive and interesting years of collaborative work, the Optogenerapy Project arrived at its end. This project, funded by the European Union’s Horizon 2020 research and innovation program (agreement No 720694), had the aim to develop and demonstrate a new optogenetics implant for controlled beta interferon (IFN-ß) protein delivery for treating Multiple Sclerosis patients.
The consortium, led by Eurecat, is composed of 11 partners, including universities, research institutions, and private companies. ASE Optics Europe was in charge of optical design, development, and integration inside the chip of the light transport system, which will ensure a homogeneous illumination of the cell chamber (more details in the special post here).
In the following video, you will see our Head of R&D sharing his experience working on the project:
